News

Progress Software Prepares for Q3 Earnings with Analyst Insights

Progress Software Prepares for Q3 Earnings with Analyst Insights

Progress Software Earnings Announcement

Progress Software Corporation (NASDAQ: PRGS) is on the brink of releasing its third-quarter earnings results. This announcement is set to come after the market closes, marking an important moment for both the company and investors alike.

Quarterly Earnings Expectations

According to analyst forecasts, Progress Software is expected to report earnings of $1.30 per share. This figure represents a notable increase from $1.26 per share reported in the same quarter last year. Furthermore, the company anticipates quarterly revenue of $240.11 million, significantly higher than the $178.69 million reported a year ago. This projected growth reflects the company’s ongoing efforts to enhance market presence and operational efficiency.

Recent Performance Highlights

In its previous quarter, Progress Software exceeded earnings expectations, a move that has likely set a positive tone leading into this upcoming announcement. Following this announcement, shares of Progress Software saw a slight uptick, closing at $41.20 recently.

Analyst Ratings Overview

Recent insights from analysts suggest a mixture of cautious optimism and confidence in the company's trajectory. Here's a closer look at how some of the most accurate analysts have rated Progress Software:

Citigroup Insights

Analyst Fatima Boolani from Citigroup maintained a Neutral rating but adjusted the price target from $64 down to $57. Despite this revision, Boolani holds an impressive accuracy rate of 78%. This suggests a measured approach toward the stock's potential.

Wedbush Recommendation

On a more optimistic note, Wedbush analyst Daniel Ives reiterated an Outperform rating, holding a price target at $75. With an accuracy rate of 83%, Ives' endorsement demonstrates confidence in Progress Software's ability to deliver value.

Guggenheim’s Perspective

Another significant endorsement comes from Guggenheim analyst John Difucci, who has reiterated a Buy rating on the stock with an elevated price target of $83. This shows a healthy outlook on the company’s potential, backed by an accuracy rate of 68% from Difucci.

Jefferies Outlook

Jefferies' Brent Thill maintained a Hold rating but increased the price target from $65 to $70, reflecting renewed optimism in the company's performance. Thill has an impressive accuracy rate of 77%, further demonstrating confidence in the stock.

Oppenheimer’s Analysis

Lastly, Oppenheimer’s Ittai Kidron kept an Outperform rating while also raising the price target from $70 to $80. This analysis, although tentative, marks a distinct vote of confidence, coupled with an accuracy rate of 71%.

Summarizing Analyst Thoughts on PRGS Stock

So, what should investors take away from these ratings? There is a consensus among analysts that Progress Software holds promise, though opinions vary regarding the stock's immediate valuation. While some analysts advocate for a more cautious approach, others express unwavering confidence in the stock’s growth potential.

Frequently Asked Questions

What date will Progress Software announce its Q3 earnings?

Progress Software is scheduled to announce its third-quarter earnings after the market closes on the relevant date.

What earnings per share (EPS) is expected?

Analysts predict Progress Software will report an EPS of $1.30 for the quarter.

How does this quarter's expected revenue compare to last year?

This quarter, Progress Software expects to generate approximately $240.11 million in revenue, compared to $178.69 million in the same period last year.

Which analysts have recent ratings on PRGS stock?

Analysts from Citigroup, Wedbush, Guggenheim, Jefferies, and Oppenheimer have all provided recent ratings and price targets for PRGS stock.

Why is analyst accuracy important?

Analyst accuracy provides insights into the credibility of their assessments and can influence investor confidence and decision-making.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 305

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 310

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 0

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 0

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 277

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Breakthroughs in Lung Cancer Treatment with Reqorsa

Updated Category News Views 182

Innovative Advances in Lung Cancer Treatment The fight against lung cancer continues to evolve, showcasing promising advancements that bring new hope to patients. Genprex, Inc. is at the forefront of this battle with its revolutionary gene therapy known as Reqorsa. This cutting-edge treatment has been developed specifically to target KRAS mutation in non-small cell lung...

Continue Reading
EfTEN United Property Fund Reports October Earnings and NAV

Updated Category News Views 192

Insights into EfTEN United Property Fund's Recent Performance EfTEN United Property Fund demonstrated a net profit of 110 thousand euros for October, totaling 2.214 million euros for the first ten months of the year, marking a significant improvement from 724 thousand euros during the same period last year. This impressive financial outcome led to a distribution to...

Continue Reading
Cardiff Oncology Reports Encouraging Results in mCRC Trial

Updated Category News Views 236

Cardiff Oncology Reveals Promising Clinical Trial Results Cardiff Oncology, Inc. (Nasdaq: CRDF), a pioneering clinical-stage biotechnology company, has recently announced encouraging results from its ongoing CRDF-004 clinical trial. This randomized Phase 2 trial is investigating the effects of onvansertib in patients suffering from first-line RAS-mutated metastatic...

Continue Reading
Japan's Growing Casting Polyurethane Market and Its Future

Updated Category News Views 127

Japan's Casting Polyurethane Market: A Rising Force The Japan casting polyurethane market is on the verge of significant transformation, anticipated to elevate from a valuation of US$ 134.74 million to a remarkable US$ 248.24 million by 2033. This growth trajectory highlights a compelling compound annual growth rate (CAGR) of 7.08%, revealing the underlying strength...

Continue Reading
Hudson Technologies Faces Challenges Amid Downgrade by B.Riley

Updated Category News Views 353

B.Riley Downgrades Hudson Technologies Stock In a recent market statement, B.Riley has lowered its outlook on Hudson Technologies (NASDAQ: HDSN), shifting the stock rating from Buy to Neutral. This adjustment comes amidst new growth projections adjusted downwards from +16.6% to +8.5%. The modification in expectations has been linked to ongoing pressures on...

Continue Reading